AR and neutropenia: In case of metastatic hormone-sensitive disease (mHSPC) and first-line therapy for metastatic castration-resistant disease (mCRPC), androgen-receptor-axis targeted therapies (ARATs) in addition to ADT are the preferred option over systemic docetaxel-based chemotherapy to reduce the risk of neutropenia during the pandemic (8).